Drug Combo Tackles Brain Mets in Breast Cancer

Brain MetsBy Crystal Phend, Senior Staff Writer, MedPage Today
Published: November 01, 2012
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse Planner

The combination of the biologic lapatinib (Tykerb) and capecitabine (Xeloda) chemotherapy appears to shrink brain metastases from HER2-positive breast cancer without need for radiation, a phase II trial showed.

Two-thirds of patients saw their previously-untreated brain lesions shrink by at least half with the treatment regimen, Thomas Bachelot, MD, of the Centre Léon Bérard in Lyon, France, and colleagues found in the LANDSCAPE trial. [Read more…]

Current Trends in the Treatment for Brain Metastasis

Antonio Marcilio Padula Omuro is an Attending Physician at the Hôpital Pitié-Salpétrière in Paris. He has published several papers on brain tumours and is a member of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Dr Omuro trained in neurology at the University of São Paulo, Brazil, and in clinical neuro-oncology at the Memorial Sloan-Kettering Cancer Center, New York.

Brain metastasis is a feared complication of cancer that is associated with a significant decrease in quality of life and a dismal prognosis. The risk of developing brain metastasis has been estimated at around 25% in all cancer patients; however, this incidence has been increasing in many common cancer types, particularly breast and NSCLC. This can be explained by several factors including the inability of certain chemotherapy agents to cross an intact blood–brain barrier (BBB), as well as an inherent propensity for the development of brain metastasis observed in long-term cancer survivors. [Read more…]